A Cardiac Safety Study of Tivozanib to Evaluate the Electrocardiogram and Pharmacokinetic-Electrocardiogram Dynamics in Subjects With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

March 31, 2011

Study Completion Date

July 31, 2011

Conditions
Advanced Solid Tumors
Interventions
DRUG

tivozanib

1 x 1.5 mg capsule of tivozanib orally once daily for 21 days

Trial Locations (8)

Unknown

TGEN Clinical Research Service at Scottsdale Healthcare, Scottsdale

Florida Cancer Specialists, Fort Myers

Horizon Oncology Research, Inc., Lafayette

Jayne Gurtler MD, Laura Brinz MD, Angelo Russo MD and Janet Burroff MD APMC, Metairie

Associates in Oncology/Hematology, Rockville

Oklahoma University Cancer Institute (OUCI), Oklahoma City

Tennessee Onocology, Nashville

Multicare Research Institute/Tacoma General Hospital, Tacoma

Sponsors
All Listed Sponsors
lead

AVEO Pharmaceuticals, Inc.

INDUSTRY